- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03923010
Recruitment Status Recruiting
First Posted April 22, 2019
Last update posted August 5, 2020
The purpose of this study is to estimate the proportion of participants prescribed itraconazole for Tinea cruris or Tinea corporis who have clinical response after 7 days of treatment.
Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Clinically diagnosed with Tinea cruris or Tinea corporis with or without history of
- Are prescribed itraconazole at 200 milligram/day orally for the treatment of T. cruris
or T. corporis and taken once a day
- A woman of childbearing potential must have a negative highly sensitive serum (beta
human chorionic gonadotropin [beta hCG]) at screening on Day -3 to 0 before start of
- A woman must be (a) not of childbearing potential (b) of childbearing potential and:
Practicing a highly effective method of contraception (failure rate of less than [<] 1 percentage [%] per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study drug and until 30 days after last dose (that is, the end of relevant systemic exposure) - A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last dose of study drug Exclusion Criteria: - History of ventricular dysfunction such as congestive heart failure (CHF) or receiving treatment for CHF, liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances at any time prior to the start of study - Known achlorhydria or on treatment of gastric acidity - Presence of other dermatoses, example. psoriasis, seborrhoeic or atopic dermatitis - Infected with organism with known or established resistance to itraconazole - Co-existing fungal infection of other body area
Contact: Study Contact 844-434-4210 JNJ.CT@sylogent.com
Post Graduate Institute of Medical Education & Research (PGIMER)
Sri Ramachandra Medical Centre
Yenepoya Medical College
K J Somaiya Medical College
Lata Mangeshkar Hospital
Janssen Research & Development, LLC
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC